Metabolic Syndrome and Cardiovascular Disease Risk in patients with Depressive disorder on Antidepressive Medication
Introduction: Depression and Metabolic syndrome both are the two major public health issues. The depressive patients are at higher risk for Cardiovascular Disease (CVD). The use of antidepressant medication has been linked to CVD. Major depression is associated with activation of the inflammatory re...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2018-09-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/12029/28702_CE[Ra1]_F(SHU)_PF1(AJ_MJ_AP)_PFA(AJ_AP)_PN(AP).pdf |
| Summary: | Introduction: Depression and Metabolic syndrome both are the two major public health issues. The depressive patients are at higher risk for Cardiovascular Disease (CVD). The use of antidepressant medication has been linked to CVD. Major depression is associated with activation of the inflammatory response. Aim: To investigate the presence of metabolic syndrome, cardiovascular risk and inflammatory marker levels in depressed patients and compare it with healthy population without depression. Materials and Methods: Cross-sectional analysis was undertaken on 94 patients with the diagnosed depressive disorder from Department of Psychiatry, Sawai Man Singh Medical College Jaipur, Rajasthan, India and 50 healthy controls from the general population. The Body Mass Index (BMI), waist circumference, blood sugar, lipid parameters and high sensitive C-Reactive Protein (hs-CRP) were measured in both groups. Depressive symptoms were measured using MontgomeryAsberg Depression Rating Scale (MADRS), antidepressant medication use {Selective Serotonin Reuptake Inhibitor (SSRI)} was also reported. Metabolic syndrome prevalence was assessed based on International Diabetes Federation (IDF) guidelines. Results: The depressive subjects showed statistically significant increased blood glucose (p=0.007), and decreased High Density Lipoprotein Cholesterol (HDLC) (p=0.001) values. There were statistically significant increased hs-CRP values (3.30±2.61 mg/L) in users of SSRI antidepressant medication compared to healthy controls (1.96±0.70 mg/L). The prevalence of metabolic syndrome in depressed patients was 42.36%. Conclusion: Depressive patients are at higher risk for CVD due to a high prevalence of metabolic syndrome. These patients should be regularly monitored for CVD risk factors. |
|---|---|
| ISSN: | 2249-782X 0973-709X |